Nicole Sweeny
Vermögen: 2 Mio $ am 31.05.2026
Vermögen: 2 Mio $ am 31.05.2026
Nicole Sweeny is currently Director at Monopar Therapeutics, Inc. and Chief Commercial Officer at KalVista Pharmaceuticals, Inc. Formerly, Ms. Sweeny was Vice President-US Marketing at Shire Plc from 2017 to 2019, Vice President-Franchise Head at Takeda Pharmaceuticals U.S.A., Inc. from 2019 to 2020, and Chief Commercial Officer at Praxis Precision Medicines, Inc. from 2020 to 2023.
Ms. Sweeny completed undergraduate education at Boston College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.05.2026 | 59.291 ( 0,12 % ) | 2 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 25.07.2023 |
| MONOPAR THERAPEUTICS INC. | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| PRAXIS PRECISION MEDICINES, INC. | Corporate Officer/Principal | 31.03.2023 |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Corporate Officer/Principal | 01.07.2020 |
| SHIRE | Corporate Officer/Principal | 01.01.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Monopar Therapeutics, Inc.
Monopar Therapeutics, Inc. BiotechnologyHealth Technology Develops drugs for cancer disease | Health Technology |
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops therapies for central nervous system disorders | Health Technology |
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen